close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

84.53 -0.51 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
72 73 Next >
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.  
Via Benzinga
P/E Ratio Insights for AstraZeneca
 
Via Benzinga
AstraZeneca Plc (AZN) Q2 2023 Earnings Call Transcript
AZN earnings call for the period ending June 30, 2023. 
Via The Motley Fool
AstraZeneca Earnings Preview
 
Via Benzinga
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy. 
Via InvestorPlace
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
From AstraZeneca
Via Business Wire
Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories
Benzinga 
Via Benzinga
Topics Supply Chain
AstraZeneca Under Legal Lens, Faces Two COVID-19 Vaccine Lawsuits In London
AstraZeneca Plc (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, is reportedly under legal scrutiny as it faces two lawsuits related to its  
Via Benzinga
Topics Lawsuit
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that... 
Via Benzinga
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell. 
Via InvestorPlace
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023
These are the pharma stocks to buy at undervalued levels as they represent companies investing heavily in research and development. 
Via InvestorPlace
AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
From AstraZeneca
Via Business Wire
Cheaper Alternatives of Weight-Loss Drugs? Chinese Pharma Companies Are Working On a Local Version
Chinese pharma firms are reportedly working on producing local equivalents of advanced weight-loss medications, challenging Western pharmaceutical giants in a  
Via Benzinga
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
Is This Blue Chip Dividend Stock a Buy for Growth Investors?
The British drugmaker has been a winner for shareholders in recent years. 
Via The Motley Fool
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize... 
Via Talk Markets
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
Via Investor Brand Network
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key  
Via Benzinga
3 Pharma Stocks to Buy for Their Promising Progress
Explore the top promising pharma stocks, leading the proverbial marathon towards transformative healthcare. 
Via InvestorPlace
AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization
Earlier today, AstraZeneca plc (NASDAQ: AZN)  
Via Benzinga
European Stock Futures Surge After ECB Meeting
In the fast-paced world of finance, hot futures have emerged as a dynamic and alluring investment opportunity. 
Via Talk Markets
iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories
Bloomberg 
Via Benzinga
AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up
AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has  
Via Benzinga
US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon
Stocks appear to have shaken off Thursday's negativity and are positioned for a rebound on upbeat earnings. 
Via Benzinga
Earnings Scheduled For July 28, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today